Last reviewed · How we verify
NCT01150656
SCOR in Targeted Therapies for Infant Leukemias Project 2: Targeting Apoptosis in Leukemia in Infants
trial testing gene expression analysis in Leukemia in 50 participants. Completed.
1 May 2016
Quick facts
| Lead sponsor | Children's Oncology Group |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 June 2010 |
| Primary completion | 1 May 2016 |
Drugs / interventions tested
- gene expression analysis
- microarray analysis
- protein expression analysis
- reverse transcriptase-polymerase chain reaction
- western blotting
- laboratory biomarker analysis — full drug profile →
- pharmacological study — full drug profile →
Conditions studied
- Leukemia — all drugs for Leukemia →
Sponsor
Children's Oncology Group — full company profile →
Who can join
Under 2, any sex, with Leukemia. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
- Obatoclax mesylate activity
- Optimum in vitro combinations of obatoclax mesylate
- Pharmacodynamic (PD) biomarkers of activity
- Cell death mechanism in multiple-lineage leukemia (MLL) acute myeloid leukemia (AML)
- Disease progression in a xenograft model of MLL-rearranged infant AML
Sponsor's own description
RATIONALE: Studying the effects of obatoclax mesylate in cell samples from patients with cancer in the laboratory may help doctors learn more about the effects of obatoclax mesylate on cancer cells. It may also help doctors identify biomarkers related to cancer. PURPOSE: This research study is studying obatoclax mesylate in samples from young patients with acute myeloid leukemia.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Ionophores: Potential Use as Anticancer Drugs and Chemosensitizers.
Kaushik V, Yakisich JS, Kumar A, Azad N, et al · · 2018 · cited 58× · PMID 30262730 · DOI 10.3390/cancers10100360 -
Programmed cell death: molecular mechanisms, biological functions, diseases, and therapeutic targets.
Qian S, Long Y, Tan G, Li X, et al · · 2024 · cited 24× · PMID 39619229 · DOI 10.1002/mco2.70024 -
Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations.
Koolivand Z, Bahreini F, Rayzan E, Rezaei N. · · 2025 · cited 3× · PMID 39811307 · DOI 10.1016/j.heliyon.2024.e41355
Verify or expand the search:
- PubMed search for NCT01150656
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of gene expression analysis
Trials testing the same drug.
- NCT01567722 — Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies · terminated
- NCT01381705 — Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma · completed
- NCT01209299 — Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated Wi · completed
- NCT01487733 — Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and E · completed
- NCT01505712 — Biomarkers in Tissue Samples From Patients With Hodgkin Lymphoma Enrolled on ECOG-2496 Clinical Trial · completed
Other recruiting trials for Leukemia
Currently open trials in the same condition.
- NCT07405424 — Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia · NA · recruiting
- NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07148180 — A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: · Phase 1, PHASE2 · recruiting
Other Children's Oncology Group trials
Trials by the same sponsor.
- NCT07412002 — Quality of End-of-Life Care for Children With Cancer · not yet recruiting
- NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
- NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia · Phase 3 · not yet recruiting
- NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
- NCT06858501 — Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01150656 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Children's Oncology Group
- Last refreshed: 17 May 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01150656.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing